Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).
In an effort to combat the coronavirus (COVID-19), front-line physicians are repurposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.
At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.
Related Posts
Sound Check: Mapping Hearing Loss in the United States
The National Opinion Research Center (NORC) at the University of Chicago is nonpartisan a research organization that aims to provide objective social science and data…
New Study Reveals Prevalence of Bilateral Hearing Loss in United States
A new study published reveals the prevalence of bilateral hearing loss in the United States by severity, age, state, county, sex, ethnicity, and residency. Regarding…
Children’s Hospital of Philadelphia Performs First Gene Therapy Procedure to Treat Genetic Hearing Loss in United States
There are more than 150 different genes that have been identified as causing hearing loss. A rarer gene, the otoferlin (OTOF) gene, was identified in…